WaveMan
WaveMan · Company
IART · Integra Lifesciences Holdings Corp
> Search tickers & screens ⌘K
LIVE
← All companies

IART Integra Lifesciences (IART) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0000917520
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
117
13F, latest reported quarter

What the filings say about IART

Congress, 1 year
No trades
Last one: sale, 2024-06-18

Integra Lifesciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for INTEGRA LIFESCIENCES HOLDINGS CORP in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
GRAVES JEFFREY A
Director
BUY
2025-11-06 SECtraded 2025-11-05
9,000
$102.2K
-1.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 21.9% of the 41,086 shares held after it.
  • No other insider bought within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GRAVES JEFFREY A bought about $102.2K of IART on Nov 5, 2025, the largest insider purchase at the company since 2024; 117 funds added in the latest 13F quarter.
Schwartz Eric
EVP, Chief Legal Officer & Sec
SELL
2024-12-04 SECtraded 2024-12-03
4,070
$100.1K
-50.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 1, 2023.
  • The trade is 6.8% of the 59,511 shares held after it.
  • 1 other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Legal Officer & Sec Schwartz Eric sold about $100.1K of IART on Dec 3, 2024; 1 other insider sold within 30 days and 117 funds added in the latest 13F quarter.
McBreen Michael J.
EVP & President, CSS
SELL
2024-12-03 SECtraded 2024-12-02
1,700
$41.1K
-50.6%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Mar 7, 2023.
  • The trade is 3.0% of the 56,182 shares held after it.
  • 1 other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & President, CSS McBreen Michael J. sold about $41.1K of IART on Dec 2, 2024; 1 other insider sold within 30 days and 117 funds added in the latest 13F quarter.
Mosebrook Jeffrey
SVP, Fin & Princ Acct Officer
SELL
2024-08-20 SECtraded 2024-08-19
1,191
$25.7K
-43.4%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 9, 2023.
  • The trade is 3.3% of the 36,088 shares held after it.
  • No other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Fin & Princ Acct Officer Mosebrook Jeffrey sold about $25.7K of IART on Aug 19, 2024; 117 funds added in the latest 13F quarter.
ESSIG STUART
Exec. Chairman of the Board
BUY
2024-05-24 SECtraded 2024-05-23
52,641
$1.5M
-58.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 10.8% of the 487,922 shares held after it.
  • 1 other insider bought within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Exec. Chairman of the Board ESSIG STUART bought about $1.5M of IART on May 23, 2024, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 117 funds added in the latest 13F quarter.
32 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 27 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
117 funds bought in last quarter
more than 67% of Medical Devices
Revenue
+1.5% year over year
below 74% of Medical Devices
Margin
-31.6% net margin
below 60% of Medical Devices
Buybacks
$221.0K repurchased, FY to 2025-12-31
below 93% of Medical Devices
Short interest
12.4% of the float short (float per yahoo 2026-10-26) · 7.5 days to cover · settled 2026-09-30
more than 86% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IART

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-23.0%12M
-42%-19%+5%+28%2025-102025-122026-022026-042026-062026-082026-10 2025-11-05 · GRAVES JEFFREY A bought $102.2K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IART: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
10,684,103 sh
$191.9M
Rubric Capital Management LP
7,753,934 sh
$139.3M
Invesco Ltd.
3,749,367 sh
$67.3M
VANGUARD PORTFOLIO MANAGEMENT LLC
3,743,093 sh
$67.2M
MORGAN STANLEY
3,593,079 sh
$64.5M

Congress trades in IART

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Josh Gottheimer
Sold 2024-06-18 · disclosed 21 days later
$1,001 - $15,000
Josh Gottheimer
Sold 2024-04-05 · disclosed 40 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IART planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

IART mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Paradigm Micro-Cap Fund
$7.2M position · as of 2026-06-30
3.9%
Paradigm Value Fund
$1.4M position · as of 2026-06-30
2.6%
HARTFORD SMALL CAP VALUE FUND
$4.8M position · as of 2026-07-31
1.6%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$2.1M position · as of 2026-06-30
1.4%
Small Cap Equity Portfolio
$14.0M position · as of 2026-07-31
1.3%
ROBO Global Healthcare Technology and Innovation ETF
$772.3K position · as of 2026-07-31
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 117 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

IART financials

Revenue growth
+1.5%
XBRL, annual
Net margin
-31.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.7B
four quarters, 2025-10-01 to 2026-09-30
Net margin, TTM
+0.8%
net income over revenue, 2025-10-01 to 2026-09-30
Free cash flow, TTM
$85.8M
operating cash flow minus capex, 2025-10-01 to 2026-09-30
Debt to equity
0.65x
long-term debt only, 2026-09-30; equity 2026-09-30
Cash flow to debt
0.20x
TTM operating cash flow over long-term debt only, 2026-09-30
Return on equity
+1.2%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on assets
+0.4%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on invested capital
+2.8%
operating income after a 41.7% effective tax rate, over long-term debt only, 2026-09-30 plus average of 2025-09-30 and 2026-09-30 minus cash
Return on capital employed
+2.3%
operating income (EBIT proxy) over average of 2025-09-30 and 2026-09-30 minus current liabilities
P/E, trailing
70.06x
close 2026-10-23 over four quarters of diluted EPS, 2025-10-01 to 2026-09-30
Enterprise value
$1.4B
market value at close 2026-10-23 on 2026-10-22 shares, plus long-term debt only, 2026-09-30, minus cash 2026-09-30
FCF yield
+9.3%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$1.6B$1.6B$1.5B$1.6B
Operating income-$493.4M$28.4M$111.5M$238.9M
Net income-$516.8M-$6.9M$67.7M$180.6M
EPS (diluted)-6.74-0.090.842.16
Operating cash flow$50.4M$129.4M$140.0M$264.5M
Cash$235.0M$246.4M$276.4M$456.7M
Long-term debt$726.6M$760.5M$775.0M$775.0M
Buybacks$221.0K$52.5M$275.0M$125.0M
SEC XBRL, fiscal years, as known on 2026-10-27

IART Stock Sonar score 5/7 axes

Find similar shapesCompare

IART ranks highest on institutional and government (67th percentile) and profitability (54th), and lowest on risk and compliance (9th), among Medical Devices peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
54
Inputs
  • Return on equity+1.2% · 68 pct, sector of 183
  • Return on assets+0.4% · 69 pct, sector of 214
  • Return on invested capital+2.8% · 9 pct, sector of 36
  • Return on capital employed+2.3% · 71 pct, sector of 188
Financial health
50
Inputs
  • Debt to equity0.65x · 32 pct, sector of 159
  • Cash flow to debt0.20x · 69 pct, sector of 150
Growth
26
Inputs
  • Revenue growth, YoY+1.5% · 26 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
67
Inputs
  • Funds adding, latest quarter117 · 67 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
9
Inputs
  • Short interest, % of float+12.4% · 14 pct, sector of 240
  • Recalls per $1B revenue, 3y53.81 per $1B · 2 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+23.2% · 12 pct, sector of 198
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

IART filings, in plain words

Have members of Congress traded IART?

Yes, but not in the year to 2026-10-27; the latest on record is a sale by Josh Gottheimer dated 2024-06-18.

Read the full summary

Members of Congress have disclosed trades in IART, none in the last year; the latest on record is a sale by Josh Gottheimer dated 2024-06-18. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies